skip to main content
Idioma:
previous page 1 Resultados 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
11
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up
Material Type:
Artigo 		Adicionar ao Meu Espaço

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Flaig, Thomas W. ; Tangen, Catherine ; Daneshmand, Siamak ; Alva, Ajjai Shivaram ; Lucia, M. Scott ; McConkey, David ; Theodorescu, Dan ; Goldkorn, Amir ; Milowsky, Matthew I. ; Bangs, Rick ; MacVicar, Gary R. ; Bastos, Bruno R. ; Fowles, Jared ; Gustafson, Daniel ; Plets, Melissa ; Thompson, Ian Murchie ; Lerner, Seth P.

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.536-536 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
12
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel

Lara, Primo ; Mayerson, Edward ; Gertz, Erik ; Tangen, Catherine ; Goldkorn, Amir ; Van Loan, Marta ; Hussain, Maha H. A. ; Gupta, Shilpa ; Zhang, Jingsong ; Twardowski, Przemyslaw ; Quinn, David I. ; Vogelzang, Nicholas J. ; Thompson, Ian Murchie ; Agarwal, Neeraj

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5523-5523 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
13
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695)
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695)

Lerner, Seth P. ; McConkey, David James ; Tangen, Catherine ; Meeks, Joshua J ; Flaig, Thomas W. ; Hua, Xing ; Daneshmand, Siamak ; Alva, Ajjai Shivaram ; Lucia, M. Scott ; Theodorescu, Dan ; Goldkorn, Amir ; Milowsky, Matthew I. ; Choi, Woonyoung ; Bangs, Richard Carlton ; Gustafson, Daniel ; Thompson, Ian Murchie

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5028-5028 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
14
Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)
Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)

Black, Peter C. ; Tangen, Catherine ; Singh, Parminder ; McConkey, David James ; Lucia, Scott ; Lowrance, William Thomas ; Koshkin, Vadim S ; Stratton, Kelly Lynn ; Bivalacqua, Trinity ; Sharon, Elad ; Kassouf, Wassim ; Porten, Sima P. ; Bangs, Richard Carlton ; Plets, Melissa ; Lerner, Seth P. ; Thompson, Ian Murchie

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5022-5022 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
15
Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC)
Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC)

Wong, Risa Liang ; Duong, Mai T. ; Tangen, Catherine ; Agarwal, Neeraj ; Cheng, Heather H. ; Vogelzang, Nicholas J. ; Hussain, Maha H. A. ; Thompson, Ian Murchie ; Quinn, David I. ; Yu, Evan Y.

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.106-106 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
16
Hispanic accrual on randomized cancer clinical trials: A call to arms
Hispanic accrual on randomized cancer clinical trials: A call to arms
Material Type:
Artigo 		Adicionar ao Meu Espaço

Hispanic accrual on randomized cancer clinical trials: A call to arms

Parra, Alberto ; Karnad, Anand B. ; Thompson, Ian Murchie

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e17555-e17555 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
17
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)
Material Type:
Artigo 		Adicionar ao Meu Espaço

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)

Agarwal, Neeraj ; Tangen, Catherine ; Hussain, Maha H. A. ; Gupta, Shilpa ; Plets, Melissa ; Lara, Primo "Lucky" N. ; Harzstark, Andrea ; Twardowski, Przemyslaw ; Paller, Channing Judith ; Zylla, Dylan M. ; Zibelman, Matthew R. ; Levine, Ellis Glenn ; Roth, Bruce J. ; Goldkorn, Amir ; Vaena, Daniel A. ; Kohli, Manish ; Crispino, Tony ; Vogelzang, Nicholas J. ; Thompson, Ian Murchie ; Quinn, David I.

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5001-5001 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
18
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study

Pal, Sumanta K. ; Tangen, Catherine ; Thompson, Ian Murchie ; Haas, Naomi B. ; George, Daniel J. ; Heng, Daniel Yick Chin ; Shuch, Brian M. ; Stein, Mark N. ; Tretiakova, Maria S. ; Humphrey, Peter ; Adeniran, Adebowale ; Narayan, Vivek ; Bjarnason, Georg A. ; Vaishampayan, Ulka N. ; Alva, Ajjai Shivaram ; Zhang, Tian ; Cole, Scott Wesley ; Plets, Melissa ; Wright, John ; Lara, Primo "Lucky" N.

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.270-270 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
19
INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients
INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients

Singh, Parminder ; Efstathiou, Jason A. ; Tangen, Catherine ; Jhavar, Sameer G. ; Hahn, Noah M. ; Costello, Brian Addis ; Delacroix, Scott Edward ; Tripathi, Abhishek ; Sachdev, Sean ; Gills, Jessie ; Jani, Ashesh B. ; Bangs, Rick ; Plets, Melissa ; Vogelzang, Nicholas J. ; Thompson, Ian Murchie ; Feng, Felix Y ; Lerner, Seth P.

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.428-428 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
20
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide
Material Type:
Artigo 		Adicionar ao Meu Espaço

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

Goldkorn, Amir ; Tangen, Catherine ; Plets, Melissa ; Morrison, Gareth ; Cunha, Alexander ; Xu, Tong ; Pinski, Jacek K. ; Ingles, Sue A. ; Triche, Timothy ; MacVicar, Gary R. ; Vaena, Daniel A. ; Crispino, Anthony W. ; McConkey, David James ; Lara, Primo ; Hussain, Maha H. A. ; Quinn, David I. ; Vogelzang, Nicholas J. ; Thompson, Ian Murchie ; Agarwal, Neeraj

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5506-5506 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
previous page 1 Resultados 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (54)
  2. Livros  (4)
  3. Mais opções open sub menu

Autor/Criador 

  1. Thompson, I  (1)
  2. Resnick, M  (1)
  3. Klein, E  (1)
  4. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2001  (3)
  2. 2001Até2012  (12)
  3. 2013Até2015  (13)
  4. 2016Até2019  (19)
  5. Após 2019  (14)
  6. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Thompson, I
  2. Resnick, M
  3. Klein, E

Neste Assunto:

  1. Life Sciences & Biomedicine
  2. Science & Technology
  3. Oncology
  4. Mass Screening
  5. Cancer

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.